iberdomide
iberdomide is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including ZENBEXUS. Available dosage form: capsule.
Drug details
- Generic Name
- iberdomide
- Brand Names
- ZENBEXUS
- Application Number
- NDA221075
- Sponsor
- E.R. Squibb & Sons, L.L.C.
- NDC Codes
- 2
- Dosage Forms
- CAPSULE
- Routes
- ORAL
- Active Ingredients
- IBERDOMIDE HYDROCHLORIDE
Indications and Usage
1 INDICATIONS AND USAGE ZENBEXUS is indicated, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ZENBEXUS is a cereblon-modulating protein degrader indicated in combination with daratumumab and hyaluronidase-fihj and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. (1) This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete response (CR) at any time. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).